Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for nine companies, including New Element Pharmaceuticals, which is preparing for an IPO on the Hong Kong Stock Exchange [1][2] - New Element Pharmaceuticals is required to clarify the reasons for inconsistencies in the identification of controlling shareholders and provide a conclusive legal opinion on the matter [1] - The company must disclose details about new shareholders in the past 12 months, including their backgrounds, reasons for investment, pricing, and any potential irregularities or conflicts of interest [1][2] Group 2 - New Element Pharmaceuticals, established in 2012, focuses on developing therapies for metabolic, inflammatory, and cardiovascular diseases, particularly for gout patients [2] - The company has developed a core product, ABP-671, which has a unique chemical structure that eliminates liver toxicity risks compared to existing treatments [2] - ABP-671 is currently undergoing Phase 2b/3 clinical trials in the US and China for treating gout and hyperuricemia, with potential applications in other conditions such as chronic kidney disease (CKD) associated with hyperuricemia [2]
新元素药业拟港股上市 中国证监会要求补充说明最近12个月内新增股东的基本情况等事项
Zhi Tong Cai Jing·2025-10-31 13:54